

5.1.2e 5.1.2e 5.1.2e 5.1.2e
5.1.2e 5.1.2e

5.1.2e

5.1.2a

Van: 5.1.2e, 5.1.2e, <5.1.2e@minvws.nl>

Datum: dinsdag 02 mrt. 2021 11:41 AM

Aan: 5.1.2e, 5.1.2e, 5.1.2e <5.1.2e@dkma.dk>

Onderwerp: RE: VS: URGENT - BioNTech-Pfizer - additional doses for some MS

No reactions yet.

Verzonden met BlackBerry Work
(www.blackberry.com)

Van: 5.1.2e, 5.1.2e, 5.1.2e <5.1.2e@dkma.dk>

Datum: dinsdag 02 mrt. 2021 9:58 AM

Aan: 5.1.2e, 5.1.2e, <5.1.2e@minvws.nl>

Onderwerp: SV: VS: URGENT - BioNTech-Pfizer - additional doses for some MS

Thank 5.1.2e

Did you hear any news today?

KR 5.1.2e

-----Oprindeligt meddelelse-----

Fra: 5.1.2e, 5.1.2e, <5.1.2e@minvws.nl>

Sendt: 1. marts 2021 20:29

Til: 5.1.2e, 5.1.2e, 5.1.2e <5.1.2e@dkma.dk>

Emne: RE: VS: URGENT - BioNTech-Pfizer - additional doses for some MS

Hi 5.1.2e

My minister is not happy with the whole issue.

If we help them out today, what do we do next week with any other request?!

At the same time, blocking this is not a pretty site sight either. It gives fuel to turning to Russia or China.

My minister will contact 5.1.2e

5.1.2a

Best regards,

5.1.2e

Verzonden met BlackBerry Work

(www.blackberry.com)

Van: 5.1.2e 5.1.2e 5.1.2e <5.1.2e@dkma.dk< 5.1.2e @dkma.dk>>

Datum: maandag 01 mrt. 2021 8:11 PM


Aan: 5.1.2e 5.1.2e < 5.1.2e @minvws.nl< 5.1.2e @minvws.nl>>

Onderwerp: VS: URGENT - BioNTech-Pfizer - additional doses for some MS

Dear 5.1.2e


Has the Netherlands arrived at a position in the matter yet?

5.1.2e



3 - 4

5.1.2a



5.1.2e

5.1.2a

-----Ursprüngliche Nachricht-----

Von: 5.1.2e @ec.europa.eu [5.1.2e @ec.europa.eu]

Gesendet: Freitag, 26. Februar 2021 17:12

An: 5.1.2e @gesundheitsministerium.gv.at' <5.1.2e @gesundheitsministerium.gv.at>; 5.1.2e, 5.1.2e

<5.1.2e @gesundheitsministerium.gv.at>; 5.1.2e, 5.1.2e <5.1.2e @gesundheitsministerium.gv.at>; 5.1.2e @fagg-

afmps.be' < 5.1.2e @fag-g-afmps.be>; 5.1.2e @bda.bg' < 5.1.2e @bda.bg>; 5.1.2e 5.1.2e
 < 5.1.2e @mh.government.bg>; 5.1.2e @moh.gov.cy' < 5.1.2e @moh.gov.cy>; 5.1.2e @phs.moh.gov.cy'
 < 5.1.2e @phs.moh.gov.cy>; 5.1.2e @mzcr.cz' < 5.1.2e @mzcr.cz>; 5.1.2e 5.1.2e @vlada.cz>; 1
 BMG < @bmg.bund.de>; COVID-19-vaccines < 5.1.2e @bmg.bund.de>; 5.1.2e @dkma.dk' < 5.1.2e @dkma.dk>; 'Birgit Neale'
 < 5.1.2e @ssi.dk>; 5.1.2e 5.1.2e < 5.1.2e @sm.ee>; 5.1.2e @sm.ee' < 5.1.2e @sm.ee>; 5.1.2e @kontozamanis.gr';
 5.1.2e @moh.gov.gr' < 5.1.2e @moh.gov.gr>; 5.1.2e @acmps.es' < 5.1.2e @acmps.es>; 5.1.2e @acmps.es' < 5.1.2e @acmps.es>;
 5.1.2e @formin.fi' < 5.1.2e @formin.fi>; 5.1.2e @stm.fi' < 5.1.2e @stm.fi>; 5.1.2e 5.1.2e
 5.1.2e @jgf.finances.gouv.fr>; 5.1.2e (5.1.2e)' < 5.1.2e @sg.social.gouv.fr>; 5.1.2e 5.1.2e
 5.1.2e @cabinets.finances.gouv.fr>; 5.1.2e 5.1.2e < 5.1.2e @miz.hr>; 5.1.2e @hzjz.hr'
 5.1.2e @hzjz.hr>; 5.1.2e @emmi.gov.hu' < 5.1.2e @emmi.gov.hu>; 5.1.2e @emmi.gov.hu'
 5.1.2e @emmi.gov.hu>; 5.1.2e @hse.ie' < 5.1.2e @hse.ie>; 5.1.2e @health.gov.ie' < 5.1.2e @health.gov.ie>;
 5.1.2e @sanita.it' < 5.1.2e @sanita.it>; 5.1.2e @vvkt.lt' < 5.1.2e @vvkt.lt>; 5.1.2e @ms.etat.lu'
 5.1.2e @ms.etat.lu>; 5.1.2e @ms.etat.lu' < 5.1.2e @ms.etat.lu>; 5.1.2e @gov.mt'
 5.1.2e @gov.mt>; 5.1.2e @vmnvd.gov.lv' < 5.1.2e @vmnvd.gov.lv>; 5.1.2e @vmnvd.gov.lv' < 5.1.2e @vmnvd.gov.lv>;
 5.1.2e @urpl.gov.pl' < 5.1.2e @urpl.gov.pl>; 5.1.2e @urpl.gov.pl' < 5.1.2e @urpl.gov.pl>;
 5.1.2e @infarmed.pt' < 5.1.2e @infarmed.pt>; 5.1.2e 5.1.2e 5.1.2e < 5.1.2e @infarmed.pt>; 5.1.2e @ms.ro' < 5.1.2e @ms.ro>;
 5.1.2e @ms.ro' < 5.1.2e @ms.ro>; 5.1.2e @gov.se' < 5.1.2e @gov.se>; 5.1.2e @gov.si'
 5.1.2e @gov.si>; 5.1.2e @health.gov.sk' < 5.1.2e @health.gov.sk>; 'Driece, R.A.' < 5.1.2e @minvws.nl>;
 5.1.2e @minbuza.nl' < 5.1.2e @minbuza.nl>; 5.1.2e @gov.si; 5.1.2e @commissariat.fed.be'
 5.1.2e @commissariat.fed.be>; 5.1.2e @health.gov.ie' < 5.1.2e @health.gov.ie>
 Cc: 5.1.2e 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e 5.1.2e
 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e 5.1.2e
 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e 5.1.2e
 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e
 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e 5.1.2e
 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e 5.1.2e
 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e | 5.1.2e @ec.europa.eu

Betreff: URGENT - BioNTech-Pfizer - additional doses for some MS

Dear Members of the Steering Board,

As discussed during the Steering Board of today, please find attached the table explaining how the allocation of doses would go to the SOS Member States (CZ, SK, AT), if you all agree with it.

BioNTech-Pfizer would like to make the following very clear:

1. "These 300K doses will not affect the doses other member states will receive in March or April. In this exceptional case, we are "accelerating" doses for AT, CZ, SK, which means we will give part of their April doses early in March. Therefore reducing them from April allocations only for these 3 markets.
2. The plan was to deliver these doses in the week commencing March 8th but now that they cannot put the orders today, these doses will probably be delivered in w/c March 15th."

Could you please let us know whether you agree with this approach by responding to EC-Vaccines functional mailbox, asap?

Thanks a lot in advance for your cooperation.

Best regards,

5.1.2e

PS: BioNTech-Pfizer informed us that they would shortly and directly liaise with all Member States on the April weekly delivery schedule.

5.1.2e | 5.1.2e
5.1.2e

European Commission
Directorate-General for Health and Food Safety (SANTE)

Unit Health security and vaccination | 5.1.2e

HITEC 02/65
L-2557 Luxembourg

+3 5.1.2e
5.1.2e @ec.europa.eu < 5.1.2e @ec.europa.eu >

<SOS theoretical pro rata calculation.xlsx>

<BioNTech-Pfizer_SOS_Allocation.xlsx>